1. Personalizing COPD Therapy According to Recent Clinical Trial Evidence

3. Introduction

4. Therapeutic Recommendations

5. Therapeutic Recommendations in Groups B and D

6. Bronchodilators in Stable COPD

7. ICS in Stable COPD

8. COPD Potential AEs of ICS Treatment

10. Diabetes Onset on ICS

11. FLAME: IND/GLY vs SFC for COPD Exacerbations in High-Risk Population

12. FLAME: Primary Endpoint Noninferiority and Superiority for IND/GLY vs SFC

13. FLAME: Effect of IND/GLY on Time to First Exacerbation Compared With SFC

14. Triple Studies Comparisons

15. Triple Studies Comparisons (cont)

16. TRIBUTE LABA/LAMA/ICS vs LABA/LAMA

17. TRIBUTE Rate of Moderate and Severe Exacerbations

18. TRIBUTE Main AEs and Serious AEs

19. IMPACT LABA/LAMA/ICS vs LABA/ICS + LABA/LAMA

20. Evolution of Exacerbations

21. IMPACT Effect on Pneumonia

22. SUNSET Trial Design

23. Primary Endpoint: Change From Baseline in Postdose Trough FEV1 (Noninferiority Analysis)

24. SUNSET Rate of COPD Exacerbations During the 26-Week Treatment Period

25. Exacerbation Rate Analysis and Blood Eosinophil Levels

26. WISDOM: ICS Withdrawal Did Not Increase the Exacerbations in Patients With Severe COPD

27. WISDOM Post-Hoc Analysis ICS Withdrawal and Exacerbation Risk

28. DYNAGITO Study Design: Tiotropium and Olodaterol in the Prevention of COPD Exacerbations

29. DYNAGITO Study Design: Tiotropium and Olodaterol in the Prevention of COPD Exacerbations (cont)

30. GOLD Recommendations in the Group D

31. Airway Obstruction and Lung Hyperinflation in COPD Are Linked to an Impaired Left Ventricular Diastolic Filling

32. Interaction of Heart and Lung in COPD Hyperinflation vs Diastolic Filling

33. CLAIM Study Design

34. CLAIM Study Results

35. Lung Deflation With Indacaterol/Glycopyrronium Improves Pulmonary Microvascular Blood Flow

36. Concluding Remarks

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)